L-oxiracetam Enantiomer Segmentation for Coma Wakefulness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coma, particularly those induced by alcoholism, narcotics, and trauma, have limited effectiveness in improving arousal and cognitive function, leading to high mortality rates and prolonged recovery times.
Innovation Solution
The use of 99.3% purity L-oxiracetam and oxiracetam in pharmaceutical formulations, such as capsules and injections, to treat or prevent coma, with specific dosages ranging from 5-90 mg/kg/day, leveraging their ability to enhance brain ATP, acetylcholine synthesis, and nerve conduction to promote wakefulness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If racemic oxiracetam is used for treating coma, then the treatment coverage is broad, but the efficacy is limited and mortality rate remains high
Solution Approach 1:
The racemic oxiracetam is segmented into its two enantiomeric components (L-oxiracetam and D-oxiracetam). The patent specifically identifies and utilizes L-oxiracetam as the active component responsible for wake-promoting effects, separating it from the less effective D-isomer to achieve higher treatment efficacy with reduced dosage requirements.
Solution Approach 2:
The patent changes the stereochemical parameter of the drug from racemic mixture to pure L-enantiomer form. This parameter change results in significantly improved pharmacological activity, better bioavailability, and enhanced wake-promoting effects compared to the racemic formulation.
2Reliability
If L-oxiracetam is used as a single drug, then the solubility and bioavailability are improved, but there are no prior reports on its use as a monotherapy for coma
Solution Approach 1:
L-oxiracetam's improved solubility and bioavailability properties enable it to serve effectively as a monotherapy without requiring combination with other drugs. The enhanced pharmacokinetic profile allows the single agent to achieve sufficient therapeutic levels in the brain for effective coma treatment.
3Ease of manufacture
If basic conditions are used in the preparation method, then L-oxiracetam can be produced, but the purification process becomes complex requiring multiple resin treatment steps
Solution Approach 1:
The patent uses cation exchange resin as an intermediary substance to facilitate the purification of L-oxiracetam from the reaction mixture. The resin acts as a mediator that selectively binds and removes impurities, allowing the product to be purified through filtration and subsequent treatment steps.
Data Source
AI summary
The present invention is to provide uses of the L-oxiracetam in preparation of medicines for preventing or treating coma. Experimental results show that L-oxiracetam wake-promoting effects of alcoholism-induced coma is obvious, and D-oxiracetam has basically no effect. The effect of the above wake-promoting effects of L-oxiracetam is 2 times greater than racemic oxiracetam. The wake-promoting effects of L-oxiracetam on trauma or anesthesia-induced coma are both significant.